Pharma Continental Pipeline

Abstract

While Africa has the capacity to operate beyond the validations in the pharmaceutical industry, it is observed that Africa serves the primary function of a validation pipeline for Northern drug development. The analysis conducted through March 2026, using lead-sponsor metadata, revealed that Africa operates from a validation perspective in clinical trials, which does not fully benefit the continent. The evidence emerges from the data of the top pharmaceutical sponsors among 23,873 African trials on ClinicTrials.gov, which indicates that the three largest global pharmaceutical companies, including Pfizer, AstraZeneca, and GlaxoSmithKline, dominate in the African trial landscape, sponsoring only for validation purposes (clinical trial phase 3), rather than the early-phase discovery, which could fully benefit the African continent. The analysis also revealed that Africa hosted 140 adaptive trials and 20 Bayesian-design trials, compared with the United States of America, which hosted 2,986 and 494, both adaptive and Bayesian-design trials, respectively. Additionally, open-label trials showed 1,545 in Africa, far below 23,963 done in the United States. Such a huge margin further testifies that African trial centers are primarily for validation and not for innovation purposes. These findings indicate that Africa benefits little or none in the clinical trial landscape, as the drugs are moved by the pharmaceutical continental pipeline from Northern laboratories to Africa for validation, and then to the Northern laboratories for global regulatory approval. Lastly, the findings further indicate that only the lead sponsor controls the interpretation, which may hinder more complex sponsorship arrangements from truly benefiting the African trial centers.